ADMA Biologics, Inc. (ADMA) company profile

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. It operates through two segments: ADMA BioManufacturing and Plasma Collection Centers. Its commercial therapies include ASCENIV and BIVIGAM, which treat primary humoral immunodeficiency, and Nabi-HB for hepatitis B exposure. The company also offers contract manufacturing and laboratory services. Its products serve physician specialists, hospitals, home infusion providers, and clinics treating immune-compromised patients, while collected plasma is also distributed to third-party manufacturers.

Headquartered in Ramsey, New Jersey, ADMA operates a plasma fractionation and purification facility in Boca Raton, Florida, capable of processing up to 600,000 liters annually. The company also maintains source plasma collection centers across the United States. Beyond domestic operations, several collection centers maintain regulatory approvals from South Korea's Ministry of Food and Drug Safety, and ADMA supplies plasma and products to customers in the United States and select international markets.

Summary of the business section of ADMA Biologics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Per Share Total Public offering price $ 8.50 $ 28,499,998 Underwriting discount and commission (1) $ 0.68 $ 2,000,000 Proceeds to us, before expenses $ 7.82 $ 26,499,998 (1) In addition, we have agreed to reimburse the underwriters for certain out-of-pocket expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had a total of 647 employees, seven of whom are part-time.”